Eyestem develops scalable cell replacement therapies using induced pluripotent stem cells to create retinal pigment epithelium (RPE) cells for treating Dry Age-related Macular Degeneration (AMD), a leading cause of blindness in individuals over 60. The company aims to democratize access to these therapies by embedding efficient manufacturing and quality processes, significantly reducing the time to market.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ALBEFounders
Product
Problem
Dry Age-related Macular Degeneration (AMD) is a leading cause of blindness in individuals over 60, affecting millions worldwide. Current treatment options are limited, and there is a need for scalable and effective cell replacement therapies to address this unmet need.
Solution
Eyestem is developing cell replacement therapies using induced pluripotent stem cells (iPSCs) to generate retinal pigment epithelium (RPE) cells for the treatment of Dry AMD. Their approach focuses on creating a scalable cell therapy platform by embedding efficient manufacturing and quality processes. The company's lead product, Eyecyte-RPE™, is designed to replace damaged RPE cells in the eye, potentially restoring vision for patients with Dry AMD. Pivotal efficacy and safety studies for Eyecyte-RPE™ have commenced, with first-in-human studies anticipated.
Target Audience
The primary target audience includes individuals over 60 suffering from Dry Age-related Macular Degeneration (AMD) and the ophthalmologists and medical centers treating this condition.
Features
- Uses induced pluripotent stem cells (iPSCs) to generate RPE cells.
- Developing Eyecyte-RPE™ for treating Dry AMD.
- Scalable cell therapy platform with embedded manufacturing and quality processes.
- Aims to democratize access to cell therapies.
- Currently undergoing pivotal efficacy and safety studies.